Posts By: John Maraganore, Ph.D.

February 28, 2018 RNAi Therapeutics: From Eureka! Moment to a Potential New Class of Medicines How far science and technology have come! At Alnylam, we believe we’re on the verge of a landmark moment in medicine and I can’t help but express my... Read More ›
September 2, 2019 ORION-11: A Landmark Event for RNAi Therapeutics The results from the ORION-11 Phase 3 study of inclisiran, presented earlier today at the European Society of Cardiology meeting represent a landmark event... Read More ›
April 11, 2019 Letter to the Editor: Federal Research is Important, but Companies Turn it Into Actual Tre ... John Maraganore wrote a Letter to the Editor in The Washington Post about the importance of federal research... Read More ›

FOLLOW US

Visit our social channels to learn more about the innovative work we are doing at Alnylam.

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site